LIVE POLIO IRUS VACCINES

Index
629
Spread-continued
in the community, 143, 161-173, 601
intra-familial pattern, Costa Rica, 184
in twins, 306
limited capacity, 143-144
Minnesota community, 161-173
no harmful effects, 601
of enteroviruses, 262
of wild and attenuated poliovirus, 172, 430
related to infectivity, 152, 181-182, 520
results, 517
significance, Philadelphia, 1959, 281
southern Louisiana, 144-155
within CNS, 98
Spigland, I., paper 377-385
"Spillover"
versus multiplication, 100
Spinal cord
invasive capacity of polio from muscle, 23
traumatic changes, 28
Stability
during production and human passage, 124
meaning, two essential characteristics, 7
of T- character after passage in monkey CNS,
23
pH and CPE inhibition, 267
refrigerated storage, 437
two methods to gauge, 7
virus progeny cannot be stable, 7, 29
Standardization
need for, 156
Stanczyk, R., paper 522-531
Statistical analysis
controls corrected on census basis, 506
impossible on small number of cases, 463
neurovirulence failure, 50
Sterne, Laurence
obstinacy and perseverance, 8
Steroids treatment
and vaccination, 602
Stomach
high acidity in infants and infection rate, 45
Strandstrom, Helena, paper 533-546
Streptomycin
in stool suspensions, 536
Stuart-Harris, C. H., 109-110, 124, 128, 174, 431,
505-506, 532, 574-576
Study population
Dade County, Florida, described, 446
Negroes, 303
Puerto Rican, 315
Success
beyond tin anniversary, 9
Suckling mice
enterovirus isolation, 368
fecal samples examined, 377
vaccine test, 505
Summer
analysis of polio among vaccinated, 464
and winter vaccination, compared, 251
vaccination campaign, reasons, 582
Suppression
markers closely situated in gene and covariation, 49
Surgery
and vaccination, 602
Surveillance
Cincinnati, 592
indicate future steps, 594
interpretation, 457
medical and nursing, continuous, 345
objectives, 593
organization and findings, Costa Rica, 569-573
Philadelphia, 1959, 279
procedures, 446
program expanded for seasonal epidemic, 547
Susceptibility, see also Morbidity
child population, 278, 492
estimation, 490
naturally occurring immunization, 595
Netherlands population, 134
newborn infants, 288, 299, 304, 313
premature infants, 288, 292
response to vaccination, 283
spread, related to type, 171
status, natural and artificial, 559
unknown factors of, 39
Sweden
field trial, 187-190
Sweet, B. H., paper 79-85; 67
Swinney filter, 124
Switzerland
field trial, 322-323
Type 1 specimens, 124
Synergistic effect
vaccine associated cases, a possible result of, 459
Syrup, 199, 507
T marker
and reappearance of monkey virulence, 34
criteria for vaccine, 31
in Esthonian polio isolates, 431
of Lederle viruses, 33
T+ isolated from contact children, 39
value not established, 37
T marker
and covariation, 49
behavior of cold mutants in humans 101-108
capacity to multiply at 40°C, 28, 109
Carp test, described, 64
compared reproductive capacity temperature, 66,
101
correlation with d character and monkey neurovirulence,
12-25, 118
correlation with virulence, 18-19, 23, 37, 125, 127,
139, 140-141
effect on plaque formation, 188
in monkey-kidney culture, 137
Mahoney and LSc not suitable controls, 132
most practical label in use, 7
not stable, 110, 480
related to d marker, 16, 113, 189
seed virus parallel, 132
studies on isolates, 16, 57, 67, 127, 141, 199, 464.
469